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Abstract 
Objectives. To determine whether there is a relation between statin utilization and coronary heart 
disease (CHD) mortality in populations with different levels of coronary risk, and whether the 
relation changes over time. 
Design. Ecological study using national databases on dispensed medicines and mortality rates. 
Setting. Western European countries with similar public health systems. 
Main outcome measures. Population CHD mortality rates (rate/100.000) as a proxy for population 
coronary risk level, and statin utilization expressed as Defined Daily Dose per one Thousand 
Inhabitants per Day (DDD/TID), in each country, for each year between 2000 and 2012 ?WĞĂƌƐŽŶ ?Ɛ
correlation coefficients between CHD mortality and statin utilization were calculated. Linear 
regression analysis was used to assess the relation between changes in CHD mortality and statin 
utilization over the years. 
Results. Twelve countries were included in the study. There was a wide range of CHD mortality 
reduction between the years 2000 and 2012 (from 25.9% in Italy to 57.9% in Denmark) and statin 
utilization increase (from 121% in Belgium to 1,263% in Denmark). No statistically significant 
relations were found between CHD mortality rates and statin utilization, nor between changes in 
CHD and changes in statin utilization in the countries over the years 2000 and 2012. 
Conclusions. Among the Western European countries studied, the large increase in statin 
utilization between 2000 and 2012 was not associated with CHD mortality, nor with its rate of 
change over the years. Factors different from the individual coronary risk, such as population 
ageing, health authority programs, guidelines, media attention and pharmaceutical industry 
marketing, may have influenced the large increase in statin utilization. These need to be re-
examined with a greater emphasis on prevention strategies. 
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Article summary 
Strengths and limitations of the study 
This is the first study to examine the relation over time between statin utilization and coronary 
heart disease (CHD) in Western European countries 
We did an ecological study investigating whether the rate of increase in statin utilization was 
associated with the rate of decrease in CHD mortality among a sample of Western European 
countries in the period 2000-2012. 
The sample of countries had a wide range of CHD mortality rates and similar public health 
systems. 
CHD mortality was used as a proxy measure of population cardiovascular risk levels. 
Limitations include a small sample size and the lack of data regarding: the patients ? adherence to 
statin treatment, the indications for statin treatment, whether primary or secondary prevention, 
ĂŶĚ ƚŚĞ ĞĨĨĞĐƚƐ ŽĨ ƉŚĂƌŵĂĐĞƵƚŝĐĂů ŝŶĚƵƐƚƌŝĞƐ ĐĂŵƉĂŝŐŶƐ ŽŶ ĚŽĐƚŽƌƐ ? ĚĞĐŝƐŝŽŶƐ ĂďŽƵƚ ƐƚĂƚŝŶ
treatment in different countries. 
 
Introduction 
A substantial decrease in CHD mortality has been observed in Western European countries during 
the last four decades,1,2 to a great extent attributable to reductions in major risk factors in the 
populations, mainly dyslipidemia and hypertension.3-5 
Statins reducing cholesterol synthesis began to be used in the 1990s cholesterol synthesis. Several 
clinical trials in both primary and secondary prevention have shown that statins reduce coronary 
events and mortality.6,7 Since their introduction, the utilization of statins has increased rapidly in 
all Western European countries, although the level of utilization varies widely.8-10 Current 
guidelines on CHD prevention propose that the decision to start statin treatment in primary 
prevention should be based on the assessment of the global risk of developing CHD in individual 
patients.11,12 According to the guidelines, the treatment of high-risk individuals should be 
prioritized. This has resulted in multiple strategies among Western European countries to enhance 
the prescribing of statins in high-risk individuals, including producing and disseminating guidelines, 
quality indicators, such as targets for lipid levels, and financial incentives.13 A reasonable 
consequence, at the population level, could be that more people are treated in high-risk countries, 
leading to a higher utilization of statins in these countries compared to low-risk ones. At the same 
time, of course, statin utilization should lower the risk by time, which makes prediction more 
complicated. 
It has previously been reported that doctors tend to underestimate coronary risk in high-risk 
patients,14 and that statins are overused for individuals with low cardiovascular risk, whereas they 
are underused for those at high risk.15,16 This may result in under-treatment of high-risk patients 
3 
 
 
whereas low-risk individuals may be unnecessarily treated, potentially leading to adverse effects 
and increased expenditure. Despite the debate about the appropriateness of current prescribing 
patterns and the effectiveness of strategies to target statin treatment based on CHD risk,17-19 
whether there is an association between coronary risk in the general population and statin 
utilization, and whether this persists over the years, has not been investigated. 
In the present study we analysed the relation between the changes over time in CHD mortality 
and statin utilization in a number of Western European countries with a wide spectrum of the 
level of population coronary risk. Our research questions were a) whether there would be an 
association between statin utilization and CHD mortality when different countries are compared at 
a certain point in time, and b) whether the level of change in statin utilization over the years 
would be associated with the level of decrease in CHD mortality. The analysis of these 
relationships may improve our understanding of the appropriateness of statin utilization. 
 
Methods 
This was an ecological study comparing statin utilization and CHD mortality between 2000 and 
2012, among Western European countries. The countries were chosen to reflect differences in 
population coronary risk and according to the availability of both mortality and statin utilization 
data. All countries have similar public health systems, or statutory health insurance with universal 
coverage, based on direct taxation or income-related contribution.20 
CHD mortality was used as a proxy measure of population CHD risk level, since it has less 
diagnostic variance than measurement of individual risk factors. There is evidence that countries 
with higher levels of risk factors have higher CHD mortality, and a close association has previously 
been demonstrated between changes in risk factor levels and changes in CHD mortality.21-23 Data 
with ICD10 codes I20-I25 (ischaemic heart disease, including angina, acute myocardial infarction, 
subsequent myocardial infarction, complications following acute myocardial infarction and chronic 
ischaemic heart disease) were extracted from the Organisation for Economic Co-operation and 
Development (OECD) database.24 All ages were included. To take into account the possible bias of 
different age classes in the different countries, we used age-standardised mortality data calculated 
by the OECD Secretariat using the total OECD population for 2010 as the reference population, 
expressed as rates/100,000 population. 
Utilization of statins was assessed using publicly available databases on prescription sales in the 
countries.20 The population coverage of each database was 100% (95% for the Netherlands). Since 
they represent more than 90% of lipid-lowering drugs used in all the countries studied, only statin 
utilization was analysed. To make international comparisons in different periods, the Anatomical 
Therapeutic Chemical (ATC) classification and the standard international method for estimating 
drug use across populations, the Defined Daily Dose (DDD) per one Thousand Inhabitants per Day 
(DDD/TID)25 were used. The ATC code C10AA and the 2013 DDDs update were used. 
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Statistical analysis was carried out using Stata 13 (Stata Corporation, Texas, USA). Volumes of 
statin utilization (DDD/TID) were plotted against CHD mortality rates in each country between the 
years 2000 and 2012. The panel of data was constructed using the reshape command in Stata, so 
that the values for each country were in different columns, one row for each year. Since each 
country was represented thirteen times, the cluster command in stata was used to adjust for 
repeated measures. Spearman ?Ɛ correlation coefficients between CHD mortality and statin 
utilization for each year between 2000 and 2012 were calculated. The relationship between 
changes in CHD mortality and statins over the years was studied with linear regression, using CHD 
mortality as a response and statin utilization and years as independent variables. 
Results 
There was available data from 12 countries: Finland, Scotland, Germany, Sweden, Norway, 
Denmark, Netherlands, Italy, Belgium, Spain, Portugal and France. Data from other Western 
European countries were not available or limited to few years (Ireland, Austria) or used a drug 
codification system that was not directly comparable to ATC (England and Wales). CHD mortality 
rates and statin utilization in the years 2000 and 2012 are shown in Figure 1. A wide range of CHD 
mortality reduction (from 25.9% in Italy to 57.9 in Denmark) and statin utilization increase (from 
121% in Belgium to 1,263% in Denmark) was observed between 2000 and 2012 (Table 1). There 
was no statistically significant correlation between statin utilization and CHD mortality in any of 
the years between 2000 and 2012. No significant relation was found between changes in statin 
utilization between 2000 and 2012 on the one hand and the changes in CHD mortality over the 
same period on the other hand (ɴĐŽĞĨĨŝĐŝĞŶƚ 0.35, 95%CI -0.61 to 1.33). 
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Figure 1.  Statin utilization and CHD mortality rates in the years 2000 and 2012. 
 
 
NB: CHD mortality data from OECD Health Statistics 2014.24 Italy missing data 2004-2005, Portugal missing data 2004-
2006. Statin utilization data from national databases on prescription sales in each country. Belgium data available 
from 2004 onwards, France until 2009. Statins data from databases on prescription sales. Belgium data available from 
2004 onwards. France until 2009. Scotland until 2010 
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Table 1 - Standardized CHD mortality rates/100.000 and statin utilization as DDD/TID 
________________________________________________________________________________________________________________ 
                   CHD mortality        Statin utilization    CHD mean annual Statins mean annual 
year 2000      2012          2000  2012       change (95% CI)   change (95% CI) 
_______________________________________________________________________________________________________________ 
Finland 264.6       166 17    94.9         -7.9 (-8.6 -7.2)    7.2 (6.5  W 8.0) 
Scotland 239.9       123.8 17.2   142.8        -10.2(-10.9 -9.6)    14.1(12.7-15.4) 
Germany 190.8       113.4 21.4    70.5         -7.1 (-7.8 -6.4)    4.5 (4.0  W 4.9) 
Sweden 186.6       112.7 21.8    76.3         -6.5 (-6.9 -6.1)    5.3 (4.9  W 5.6) 
Norway 173.2       87.2 30.9   114.6         -7.5 (-8.5 -6.5)    7.6 (7.1  W 8.1) 
Denmark 168       70.6 8.6   117.3         -8.5 (-9.4 -7.7)    10.3 (9.4  W 11.2) 
Netherlands 122.5       53.6 35.6    99.9         -6.0 (-6.5 -5.4)    6.3 (5.8  W 6.8) 
Italy  113.5       84.1 6.4    64.5         -2.7 (-3.4 -2.0)    4.8 (4.6  W 5.0) 
Belgium 121.3       62.6 50.9   112.7         -5.1 (-5.6 -4.7)    8.5 (7.8  W 9.3) 
Spain  94       59.5 14.7    91.6         -3.0 (-3.3 -2.8)    6.6 (6.0  W 7.2) 
Portugal 88.6       51.7 11.1    98.9         -3.4 (-4.0 -2.9)    8.5 (7.9  W 9.2) 
France  72.8       42.6 32.3    66.0         -2.9 (-3.1 -2.7)    3.5 (2.9  W 4.1) 
__________________________________________________________________________ 
Mean           153 (60)     85 (36)       22 (13)    95 (23)       -5.9 (-7.4 -4.3)         7.2 (5.4  W 9.1) 
_______________________________________________________________________________________________________________ 
NB. Data as in Figure 1. Summary data are expressed as mean (SD) or (95%CI) 
 
Coronary mortality in 2012 was highly correlated to CHD in 2000 (p=0.002), whereas no significant 
correlation was found between statins in 2000 and 2012. 
The mean annual change in CHD mortality was plotted against the mean annual change in statin 
utilization (Figure 2). The mean annual change in statin utilization varied widely across all 
countries and was unrelated to the annual change in CHD mortality. Countries with similar 
decreases in CHD mortality rates (France, Italy, Spain and Portugal) had very different increases in 
statin utilization. Conversely, similar increases in statin utilization were observed in countries with 
very different reductions in CHD mortality rates. Scotland showed the largest rates of CHD 
mortality reduction and statin utilization increase. Taken together, the countries showed a wide 
range of statin increase, with no apparent relation to the reduction in CHD mortality. 
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Figure 2. Mean annual changes in statin utilization and CHD mortality rates between 2000 and 
2012 
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effect of statins on cardiovascular risk, or as changes in statin utilization following changes in risk 
levels. However, when the different countries were compared there was no evidence that a higher 
statin utilization was associated to a lower CHD mortality, nor that a high increase in statin 
utilization between 2000 and 2012 was related to a larger reduction in CHD mortality. 
The over-all reduced CHD mortality might be considered as an effect of the increased utilization of 
statins. Although several clinical studies have demonstrated that statins reduce the cardiovascular 
mortality in primary and secondary prevention,26-28 the decrease in CHD mortality rates in Western 
countries started well before statin therapy become available, due to improvement of risk factors, 
as a result of population-based interventions.29 Moreover, clinical trials in primary and secondary 
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demonstrate any population impact of statin utilization on CHD mortality. This was confirmed in a 
Swedish study including a large sample of municipalities, where no correlation was shown 
between statin utilization and acute myocardial infarction incidence or mortality.31 
We have recently observed that statin utilization is higher in Stockholm, Sweden, which is a 
relatively high-risk area, compared to Sicily, Italy, with a lower population risk level.32 However, 
the analysis of the time trend of changes in statin utilization and CHD mortality rates in these 
regions between 2000 and 2011 showed that statin utilization increased more rapidly in Sicily 
where the reduction in CHD mortality was slower, whereas a smaller increase occurred in 
Stockholm with a larger reduction in CHD mortality. Such discordance between time trends may 
ŝŶĚŝĐĂƚĞƚŚĂƚƚŚĞĚŽĐƚŽƌƐ ?ĂƚƚŝƚƵĚĞƚŽŝŶŝƚŝĂƚŝŶŐƐƚĂƚŝŶƚƌĞatment is influenced by factors not directly 
ƌĞůĂƚĞĚ ƚŽ ƚŚĞ ĂĐƚƵĂů ƌŝƐŬ ŽĨ ƚŚĞ ƉĂƚŝĞŶƚƐ ? ƐƵĐŚ ĂƐ ƚŚĞĚŽĐƚŽƌƐ ? ŐĞŶĚĞƌ ĂŶĚ ůĞŶŐƚŚ ŽĨ ĐůŝŶŝĐĂů
experience, patients ? attitudes to medicines, drug reimbursement policies, prescribing restrictions 
and marketing by pharmaceutical companies.13,33,34 
Interpreting the relation between statin utilization and CHD mortality cannot be limited to the 
direct relation between drug therapy and clinical outcome. Pharmaceutical expenditure has 
increased in all European countries during the last decade due to the ageing population, new and 
expensive medicines, the growing prevalence of chronic diseases, rising patient expectations and 
greater treatment intensity due to the reduction of the threshold to prevent cardiovascular 
disease.35-37 In the case of statins, health authorities in many countries have introduced measures 
to increase the prescribing of low-cost generic vs. patented statins to reduce expenditure without 
compromising care.9 Educational interventions and disease management programs have also been 
initiated by health authorities to promote the use of statins in high-risk groups, especially where 
there is perceived under-treatment. 38,39 This includes patients with diabetes and a history of 
stroke. The policy reforms conducted in the different countries have resulted in economical 
savings while also stimulating an increased prescribing of statins.13 
 
Strengths and limitations 
The populations we studied represent the real world; therefore they were different from patients 
included in clinical trials, who are highly selected.40 There was a wide range of CHD mortality rates 
among countries, which allowed analysis of changes in statin utilization in countries with different 
levels of coronary risk. 
There are some limitations to our study. We assumed that CHD mortality represented the 
population coronary risk. However, about half of the changes in CHD mortality can be explained by 
changes in risk factors, whereas the other half are due to treatment or to unknown factors.41 
Differences in the relative proportion of changes in risk factors among countries may have 
influenced the utilization of statins. This study has a limited statistical power due to small sample 
size. Ours is an ecological study, but we did not have access to information on individual patient 
link between CHD risk and statin utilization. Therefore, our results at country level may not be 
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applicable to single patients (ecological fallacy).42 A critical issue regarding the effectiveness of 
statin therapy is the persistence of treatment. Poor adherence to treatment is associated with an 
increased risk of cardiovascular disease and mortality.43 Adherence to lipid-lowering treatment 
shows wide variation, ranging from 37% to 80%, 44 with lower rates in women, young patients, 
those on low income, patients taking statins for primary prevention,45 and when a statin is 
prescribed for secondary prevention by a primary care physician, rather than a cardiologist or 
neurologist.46 Differences in the discontinuation rate of statins among countries might have a role 
in the relation between statin utilization and CHD mortality. However, we could not assess this in 
our study as we did not have access to patient specific data, but only to aggregated statin 
utilization data. 
 
We also do not know the influence of extensive marketing campaigns by the pharmaceutical 
ŝŶĚƵƐƚƌŝĞƐŽŶĚŽĐƚŽƌƐ ?ĚĞĐŝƐŝŽŶĂďŽƵƚƐƚĂƚŝŶƚƌĞĂƚŵĞŶƚŝŶĞĂĐŚĐŽƵŶƚƌǇ ?This may be an important 
factor in treatment decisions, especially targeting low-risk individuals.47 Also the media debate 
about the benefit of giving statins to all over-50s, independently from risk scoring, vs. the concern 
about adverse effects, especially myopathy and increased risk of diabetes,48-51 may have had 
different impacts both on doctors and patients in different countries. The extent of statin 
utilization for either primary or secondary prevention in each country was not investigated. Cross-
sectional studies in European countries have shown large variations in the attainment of 
treatment targets, in both primary and secondary prevention.52,53 ŽĐƚŽƌƐ ?willingness to prescribe 
statins in primary prevention may also change over time due to reimbursement changes or 
guidelines restrictions.54-56 Higher prescription rates have been reported in women and the 
elderly.31,57 There is also a socioeconomic gradient in the utilization of statins. More patients with 
higher income and educational levels start statin treatment compared to patients with lower 
income, especially in secondary prevention.58-60 The differences among countries might have 
affected the pattern for prescribing statins. 
 
 
Clinical implications 
Among the Western European countries studied, CHD mortality decreased by approximately forty 
percent whereas statin utilization increased more than threefold between 2000 and 2012. 
However, this large growth in statin utilization over the years did not appear to be related to the 
coronary risk in the population or to the changes over the years. Factors other than coronary risk, 
such as demographic changes, socioeconomic factors, healthcare policies, including educational 
programmes, and pharmaceutical industry marketing, should be taken into account to explain the 
rapid increase in statin utilization among Western European countries. On the other hand, 
although statins have proved effective in the appropriate clinical setting,6,7 whether they are 
appropriately prescribed to those who benefit most, i.e. high-risk individuals, and whether statins 
are effective and safe in otherwise healthy people, are matters for debate.61-63 Since CHD is largely 
dependent on health factors,64 such as diet and exercise, the apparent lack of association we 
observed between CHD mortality and statin utilization supports the need for greater 
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implementation of population life-style changes instead of additional initiatives to further enhance 
statin utilization to reduce the burden of CHD. 
 
Acknowledgements, contributors and conflicts of interest 
We thank Carsten Telschow, AOK Research Institute, Berlin, Iain Bishop, NHS National Services, Scotland, 
Maria Juhasz and Desirée Loikas, Stockholm County Council, Sweden, for providing statin data from 
Germany, Scotland and Sweden, respectively, and Julie Ramsey, National Records of Scotland, for 
calculating standardized Scottish CHD mortality rates. 
Contributors. FV was responsible for the design, implementation, analysis and reporting of the study. LB, L-
ES, BG and BW provided substantial contributions to the design, analysis and interpretation of data, and all 
critically revised the manuscript and approved the final version. 
Funding. This research received no specific grant from any funding agency in the public, commercial or not-
for-profit sectors 
Ethical approval. Not required. 
Competing interests. The authors declare: no support from any organization for the submitted work; no 
financial relationships with any organization that might have an interest in the submitted work in the 
previous three years; no other relationships or activities that could appear to have influenced the 
submitted work 
 
References  
1. Kesteloot H, Sans S, Kromhout D. Dynamics of cardiovascular and all-cause mortality in Western 
and Eastern Europe between 1970 and 2000. European Heart Journal 2006;27:107-13. 
2. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: 
epidemiological update. European Heart Journal 2014;35:2950-59. 
3. Palmieri L, Bennett K, Giampaoli S, Capewell S. Explaining the decrease in coronary heart disease 
mortality in Italy between 1980 and 2000. American Journal of Public Health 2010;100:684-92. 
4. Björck L, Rosengren A, Bennett K, Lappas G, Capewell S. Modelling the decreasing coronary heart 
disease mortality in Sweden between 1986 and 2002. European Heart Journal 2009;30:1046-56. 
5. Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England 
and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. BMJ 
2005;331:614. 
6. Mills EJ, WU P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a 
network meta-analysis of 170255 patients from 76 randomized trials. QJM 2011;104:109-24. 
7. Naci H, Brugts JJ, Fleurence R, Tsoi B, Toor H, Ades AE. Comparative benefits of statins in the 
primary and secondary prevention of major coronary events and all-cause mortality: a network meta-
analysis of placebo-controlled and active-comparator trials. European Journal of Preventive Cardiology 
2013;20:641-57. 
8. Walley T, Folino-Gallo P, Stephens P, Van Ganse E, EuroMedStat group. Trends in prescribing and 
utilization of statins and other lipid lowering drugs across Europe 1997 W2003. British Journal of Clinical 
Pharmacology 2005;60:543-51. 
11 
 
 
9. Godman B, Wettermark B, van Woerkom M, et al. Multiple policies to enhance prescribing 
efficiency for established medicines in Europe with a particular focus on demand-side measures: findings 
and future implications. Frontiers in Pharmacology 2014;5:106. 
10. Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a 
comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-40. 
11. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in 
clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other 
Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine 
societies and by invited experts)Developed with the special contribution of the European Association for 
Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal 2012;33:1635-701. 
12. NICE, National Institute for Health and Care Excellence. NICE clinical guideline 181. Lipid 
modification: cardiovascular risk assessment and the modification of blood lipids for the primary and 
secondary prevention of cardiovascular disease. Available at: guidance.nice.org.uk/cg181. 2014. 
13. Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in Europe: 
findings and future implications. Frontiers in Pharmacology 2011;1. 
14. Backlund L, Bring J, Strender L-E. How accurately do general practitioners and students estimate 
coronary risk in hypercholesterolaemic patients? Primary Health Care Research & Development 
2004;5:145-52. 
15. van Staa T-P, Smeeth L, Ng ES-W, Goldacre B, Gulliford M. The efficiency of cardiovascular risk 
assessment: do the right patients get statin treatment? Heart 2013;99:1597-602. 
16. Murphy C, Bennett K, Fahey T, Shelley E, Graham I, Kenny RA. Statin use in adults at high risk of 
cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study 
on Ageing (TILDA). BMJ Open 2015;5: DOI 10.1136/bmjopen-2015-008017. 
17. Brugts JJ, Deckers JW. Statin prescription in men and women at cardiovascular risk: to whom and 
when? Current Opinion in Cardiology 2010;25:484-9. 
18. Petursson H, Getz L, Sigurdsson JA, Hetlevik I. Can individuals with a significant risk for 
cardiovascular disease be adequately identified by combination of several risk factors? Modelling study 
based on the Norwegian HUNT 2 population. Journal of Evaluation in Clinical Practice 2009;15:103-9. 
19. Tunstall-Pedoe H. Starting statins for primary prevention of cardiovascular disease. Heart 
2013;99:1547-8. 
20. Drug Consumption Databases in Europe. Master document. Updated version February 2015, 
available at www.icf.uab.es/ca/pdf/publicacions/DU_inventory_master.pdf.  
21. Menotti A, Lanti M, Kromhout D, et al. Forty-year coronary mortality trends and changes in major 
risk factors in the first 10 years of follow-up in the seven countries study. European Journal of Epidemiology 
2007;22:747-54. 
22. Wijeysundera HC, Machado M, Farahati F, et al. Association of temporal trends in risk factors and 
treatment uptake with coronary heart disease mortality, 1994-2005. JAMA 2010;303:1841-7. 
23. Capewell S, Ford E, Croft J, JA C, Greenlund K, Labarthe D. Cardiovascular risk factors trends and 
potential for reducing coronary heart disease mortality in the United States of America. Bulletin of the 
World Health Organization 2010;88:120-30. 
24. OECD, Organisation for Economic Co-operation and Development. Health statistics 2014, available 
at http://www.oecd.org/health/healthdata. 
25. WHO, Collaborating Centre for Drug Statistics Methodology, ATC/DDD index 2013. 
http://www.hoccno/atc_ddd_index/WHO 2013. 
26. Taylor F, Huffman MD, Macedo AF, et al. Statins for primary prevention of cardiovascular disease. 
Cochrane Database of Systematic Reviews 2013;1 DOI: 10.1002/14651858.CD004816.pub5. 
27. Cholesterol Treatment Trialists C. The effects of lowering LDL cholesterol with statin therapy in 
people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The 
Lancet 2012. 
28. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol 
lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. The Lancet 
2002;360:7-22. 
12 
 
 
29. Ford ES, Capewell S. Proportion of the decline in cardiovascular mortality disease due to prevention 
versus treatment: public health versus clinical care. Annual Review of Public Health 2011;32:5-22. 
30. Thompson A, Temple NJ. The case for statins: has it really been made ? J R Soc Med 2004;97:461-4. 
31. Nilsson S, Molstad S, Karlberg C, Karlsson J-E, Persson L-G. No connection between the level of 
exposition to statins in the population and the incidence/mortality of acute myocardial infarction: An 
ecological study based on Sweden's municipalities. Journal of Negative Results in BioMedicine 2011;10:6. 
32. Vancheri F, Wettermark B, Strender L-E, Backlund LG. Trends in coronary heart disease mortality 
and statin utilization in two European areas with different population risk levels: Stockholm and Sicily. 
International Cardiovascular Forum 2014;3:140-6. 
33. Vancheri F, Strender L-E, Backlund LG. General Practitioners' coronary risk estimates, decisions to 
start lipid-lowering treatment, gender and length of clinical experience: their interactions in primary 
prevention. Primary Health Care Research & Development 2013;14:394-402. 
34. Sketris I, Ingram Langille E, Lummis H. Optimal prescribing and medication use in Canada. 
Challenges and opportunities. Available at http://www.healthcouncilcanada.ca/index.php. 2007. 
35. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp FM. Soft Regulations in Pharmaceutical 
Policy Making: An Overview of Current Approaches and their Consequences. Applied Health Economics & 
Health Policy 2009;7:137-47. 
36. Mousnad MA, Shafie AA, Ibrahim MI. Systematic review of factors affecting pharmaceutical 
expenditures. Health Policy 2014;116:137-46. 
37. Kildemoes HW, Støvring H, Andersen M. Driving forces behind increasing cardiovascular drug 
utilization: a dynamic pharmacoepidemiological model. British Journal of Clinical Pharmacology 
2008;66:885-95. 
38. Fraeyman J, Van Hal G, Godman B, Beutels P. The potential influence of various initiatives to 
improve rational prescribing for proton pump inhibitors and statins in Belgium. Expert Review of 
Pharmacoeconomics & Outcomes Research 2013;13:141-51. 
39. Van Woerkom M, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of 
prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. 
Journal of Comparative Effectiveness Research 2012;1:527-38. 
40. Eichler H-G, Abadie E, Breckenridge A, et al. Bridging the efficacy Weffectiveness gap: a regulator's 
perspective on addressing variability of drug response. Nat Rev Drug Discov 2011;10:495-506. 
41. ĂƉĞǁĞůů^ ?K ?&ůĂŚĞƌƚǇD ?tŚĂƚĞǆƉůĂŝŶƐĚĞĐůŝŶŝŶŐĐŽƌŽŶĂƌǇŵŽƌƚĂůŝƚǇ ?>essons and warnings. Heart 
2008;94:1105-8. 
42. Piantadosi S, Byar DP, Green SB. The ecological fallacy. American Journal of Epidemiology 
1988;127:893-904. 
43. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and 
mortality outcomes: a systematic review. British Journal of Clinical Pharmacology 2014;78:684-98. 
44. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. 
Cochrane Database of Systematic Reviews 2010;3:CD004371. 
45. Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of nonadherence to 
statin therapy: a meta-analysis. Canadian Journal of Cardiology 2012;28:574-80. 
46. Citarella A, Kieler H, Sundström A, et al. Family history of cardiovascular disease and influence on 
statin therapy persistence. European Journal of Clinical Pharmacology 2014;70:701-7. 
47. tŽůĨĞ ^ ? ZŽƐƵǀĂƐƚĂƚŝŶ P ǁŝŶŶĞƌ ŝŶ ƚŚĞ ƐƚĂƚŝŶ ǁĂƌƐ ? ƉĂƚŝĞŶƚƐ ? ŚĞĂůƚ  ŶŽƚǁŝƚŚƐƚĂŶĚŝŶŐ ?
2015;350:h13882015. 
48. McCartney M. Statins for all? BMJ 2012;345:e6044. 
49. Mansi I, Frei CR, Wang C-P, Mortensen EM. Statins and new-onset diabetes mellitus and diabetic 
complications: a retrospective cohort study of US healthy adults. Journal of General Internal Medicine 
2015;30:1599-610. 
50. Cederberg , ?^ƚĂŶēĂŬŽǀĄ ?zĂůƵƌŝE ?DŽĚŝ^ ?<ƵƵƐŝƐƚŽ: ?>ĂĂŬƐŽD ?/ŶĐƌĞĂƐĞĚƌŝƐŬŽĨĚŝĂďĞƚĞƐǁŝƚŚ
statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up 
study of the METSIM cohort. Diabetologia 2015;58:1109-17. 
51. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and 
Wales: population based cohort study using the QResearch database. 2010;340:c21972010. 
13 
 
 
52. Banegas JR, López-García E, Dallongeville J, et al. Achievement of treatment goals for primary 
prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. European Heart 
Journal 2011;32:2143-52. 
53. Kotseva K, Wood D, Backer GD, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use 
of cardioprotective drug therapies in coronary patients from 22 European countries. European Journal of 
Cardiovascular Prevention & Rehabilitation 2009;16:121-37. 
54. Pettersson B, Hoffmann M, Wändell P, Levin L-Å. Utilization and costs of lipid modifying therapies 
following health technology assessment for the new reimbursement scheme in Sweden. Health Policy 
2012;104:84-91. 
55. Damiani G, Federico B, Bianchi C, et al. The impact of Regional co-payment and National 
reimbursement criteria on statins use in Italy: an interrupted time-series analysis. BMC Health Services 
Research 2014;14:6. 
56. Martikainen JEL, Saastamoinen LKP, Korhonen MJP, Enlund HP, Helin-Salmivaara AMDP. Impact of 
Restricted Reimbursement on the Use of Statins in Finland: A Register-Based Study. Medical Care 
2010;48:761-6. 
57. Kildemoes HW, Hendriksen C, Andersen M. Drug utilization according to reason for prescribing: a 
pharmacoepidemiologic method based on an indication hierarchy. Pharmacoepidemiology and Drug Safety 
2012;21:1027-35. 
58. Selmer R, Sakshaug S, Skurtveit S, Furu K, Tverdal A. Statin treatment in a cohort of 20 212 men and 
women in Norway according to cardiovascular risk factors and level of education. British Journal of Clinical 
Pharmacology 2009;67:355-62. 
59. Thomsen RW, Johnsen SP, Olesen AV, et al. Socioeconomic gradient in use of statins among Danish 
patients: population-based cross-sectional study. British Journal of Clinical Pharmacology 2005;60:534-42. 
60. Rasmussen JN, Gislason GH, Rasmussen S, et al. Use of statins and beta-blockers after acute 
myocardial infarction according to income and education. Journal of Epidemiology and Community Health 
2007;61:1091-7. 
61. Abramson J, Wright JM. Are lipid-lowering guidelines evidence-based? The Lancet 2007;369:168-9. 
62. Golomb B, Evans M. Statin Adverse Effects. Am J Cardiovasc Drugs 2008;8:373-418. 
63. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the 
community in high-income, middle-income, and low-income countries (the PURE Study): a prospective 
epidemiological survey. The Lancet 2011;378:1231-43. 
64. Chiuve SE, McCullough ML, Sacks FM, Rimm EB. Healthy lifestyle factors in the primary prevention 
of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and 
antihypertensive medications. Circulation 2006;114:160-7. 
 
 
